Breaking News, Financial News

Bristol-Myers Squibb 3Q

Bristol-Myers Squibb

3Q Revenues: $5.1 billion (+22%)

3Q Earnings: $858 million (+154%)

YTD Revenues: $14.5 billion (+5%)

YTD Earnings: $2.3 billion (+35%)

Comments: Earnings for 3Q07 were boosted by $247 million from the sell-off of the Bufferin and Excedrin brands in Japan. Worldwide pharma sales grew 24% to $3.9 billion, but that growth rate is affected by the 3Q06 sales of generic Plavix by Apotex. The company estimated that the generic competitor sapped $525-$600 million from 3Q06 sales. Plavix sales in the U.S. were up 128% to $1.1 billion. Sales of schizophrenia/bipoolar treatment Abilify grew 34% to $420 million worldwide.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters